Literature DB >> 10900262

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

N Benali1, P Cordelier, D Calise, P Pages, P Rochaix, A Nagy, J P Esteve, P M Pour, A V Schally, N Vaysse, C Susini, L Buscail.   

Abstract

The sst2 somatostatin receptor mediates the antiproliferative effects of somatostatin analogs. The present study demonstrates that stable expression of sst2 in the hamster pancreatic cancer cells PC-1 and PC-1.0 activates an autocrine negative loop leading to an in vitro inhibition of cell proliferation. In vivo studies conducted in Syrian golden hamsters after orthotopic implantation of PC-1.0 cells showed that both tumor growth and metastatic progression of allografts containing 100% of sst2-expressing cells were significantly inhibited for up to 20 days after implantation, as compared with control allografts that did not express sst2. A local antitumor bystander effect was observed after induction of mixed tumors containing a 1:3 ratio of sst2-expressing cells to control cells. Tumor volume and incidence of metastases of mixed tumors were significantly reduced at day 13 post implantation. This effect decreased with time as at day 20, growth of mixed tumors was similar to that of control tumors. After administration of the cytotoxic somatostatin conjugate AN-238 on day 13, antitumor bystander effect observed in mixed tumors was significantly extended to day 20. We also observed that in vitro invasiveness of sst2-expressing PC-1.0 cells was significantly reduced. Tyrosine dephosphorylation of E-cadherin may participate in restoring the E-cadherin function, reducing in turn pancreatic cancer cell motility and invasiveness. This dephosphorylation depends on the tyrosine phosphatase src homology 2-containing tyrosine phosphatase 1 (SHP-1) positively coupled to sst2 receptor. The inhibitory effect of sst2 gene expression on pancreatic cancer growth and invasion combined with chemotherapy with targeted cytotoxic somatostatin analog administration provides a rationale for a therapeutic approach to gene therapy based on in vivo sst2 gene transfer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10900262      PMCID: PMC16842          DOI: 10.1073/pnas.130196697

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts.

Authors:  D W Owens; G W McLean; A W Wyke; C Paraskeva; E K Parkinson; M C Frame; V G Brunton
Journal:  Mol Biol Cell       Date:  2000-01       Impact factor: 4.138

Review 2.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

Authors:  S W Lamberts; E P Krenning; J C Reubi
Journal:  Endocr Rev       Date:  1991-11       Impact factor: 19.871

3.  Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.

Authors:  A Plonowski; A V Schally; A Nagy; B Sun; K Szepeshazi
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

4.  Classification and nomenclature of somatostatin receptors.

Authors:  D Hoyer; G I Bell; M Berelowitz; J Epelbaum; W Feniuk; P P Humphrey; A M O'Carroll; Y C Patel; A Schonbrunn; J E Taylor
Journal:  Trends Pharmacol Sci       Date:  1995-03       Impact factor: 14.819

5.  Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms.

Authors:  L Buscail; J P Estève; N Saint-Laurent; V Bertrand; T Reisine; A M O'Carroll; G I Bell; A V Schally; N Vaysse; C Susini
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters.

Authors:  H Egami; T Tomioka; M Tempero; D Kay; P M Pour
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

7.  Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.

Authors:  A Plonowski; A V Schally; A Nagy; H Kiaris; F Hebert; G Halmos
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

8.  Establishment of hamster pancreatic ductal carcinoma cell line (PC-1) producing blood group-related antigens.

Authors:  H Egami; Y Takiyama; M Cano; W H Houser; P M Pour
Journal:  Carcinogenesis       Date:  1989-05       Impact factor: 4.944

9.  Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.

Authors:  R Z Cai; B Szoke; R Lu; D Fu; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

10.  Enhanced levels of annexins in pancreatic carcinoma cells of Syrian hamsters and their intrapancreatic allografts.

Authors:  K D Kumble; M Hirota; P M Pour; J K Vishwanatha
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

View more
  29 in total

Review 1.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 2.  Non-invasive genetic imaging for molecular and cell therapies of cancer.

Authors:  C Belmar; P-W So; G Vassaux; V Moleiro-Sanemeterio; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2007-11       Impact factor: 3.405

3.  Complete regression of advanced HCC with long acting octreotide.

Authors:  J T Siveke; C Herberhold; C Folwaczny
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

4.  Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation.

Authors:  Geraldine Ferjoux; Frederic Lopez; Jean-Pierre Esteve; Audrey Ferrand; Eric Vivier; Frederic Vely; Nathalie Saint-Laurent; Lucien Pradayrol; Louis Buscail; Christiane Susini
Journal:  Mol Biol Cell       Date:  2003-07-11       Impact factor: 4.138

Review 5.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

6.  First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings.

Authors:  Louis Buscail; Barbara Bournet; Fabienne Vernejoul; Gilles Cambois; Hubert Lulka; Naïma Hanoun; Marlène Dufresne; Aline Meulle; Alix Vignolle-Vidoni; Laetitia Ligat; Nathalie Saint-Laurent; Frédéric Pont; Sébastien Dejean; Marion Gayral; Frédéric Martins; Jérôme Torrisani; Odile Barbey; Fabian Gross; Rosine Guimbaud; Philippe Otal; Frédéric Lopez; Gérard Tiraby; Pierre Cordelier
Journal:  Mol Ther       Date:  2015-01-14       Impact factor: 11.454

7.  A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway.

Authors:  Souad Najib; Nathalie Saint-Laurent; Jean-Pierre Estève; Stefan Schulz; Elisa Boutet-Robinet; Daniel Fourmy; Jens Lättig; Catherine Mollereau; Stéphane Pyronnet; Christiane Susini; Corinne Bousquet
Journal:  Mol Cell Biol       Date:  2011-12-27       Impact factor: 4.272

8.  Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.

Authors:  Min Li; Xiaochi Wang; Wei Li; Fei Li; Hui Yang; Hao Wang; F Charles Brunicardi; Changyi Chen; Qizhi Yao; William E Fisher
Journal:  Cancer Sci       Date:  2008-09-22       Impact factor: 6.716

9.  Use of H19 Gene Regulatory Sequences in DNA-Based Therapy for Pancreatic Cancer.

Authors:  V Scaiewicz; V Sorin; Y Fellig; T Birman; A Mizrahi; J Galula; R Abu-Lail; T Shneider; P Ohana; L Buscail; A Hochberg; A Czerniak
Journal:  J Oncol       Date:  2010-10-28       Impact factor: 4.375

10.  Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy.

Authors:  Naima Hanoun; Marion Gayral; Adeline Pointreau; Louis Buscail; Pierre Cordelier
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.